Sammenlign metoder

	Faststofsdispersionformulering	Caco-2 cellepermeabilitetsanalyse	f1/f2 Dissolutionslighedsfaktor
Fagområde	Farmakologi	Farmakologi	Farmakologi
Familie	Process / pipeline	Process / pipeline	Process / pipeline
Oprindelsesår	1971	1989	1996
Ophavsperson	William Chiou and Solomon Riegelman	Ingrid Hidalgo	James Moore and Hector Flanner
Type	solubility enhancement	absorption screening	similarity testing
Oprindelig kilde	Chiou, W. L., Riegelman, S. (1971). Pharmaceutical applications of solid dispersions. Journal of Pharmaceutical Sciences, 60(9), 1281-1302.	Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749.	Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74.
Aliasser	solid solution, amorphous dispersion, polymer-based formulation	Caco-2 assay, intestinal permeability, ADME screening	f1, f2, similarity factor
Relaterede	3	3	3
Resumé	Solid dispersion is a formulation technique where a poorly soluble drug is molecularly dispersed in a hydrophilic polymer matrix, improving aqueous solubility and bioavailability. Introduced by Chiou and Riegelman in 1971, solid dispersions remain a key strategy for overcoming solubility-limited absorption.	The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport.	The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release.